In a note, B. Riley FBR analyst Mayank Mamtani (Buy/$43) says today’s selloff in Genfit SA (GNFT -4.6%),
apparently over concerns with a potential delay in the development
timeline for elafibranor in NASH, is misguided considering that the
expected data readout remains on track for this quarter.
He believes the stock could double if the NASH resolution benefit is 15 – 20%.
https://seekingalpha.com/news/3534023-b-riley-fbr-defends-genfit-amid-drop
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.